

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM800515

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Newstone Capital Partners, LLC		04/04/2023	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	TerSera Therapeutics LLC		
Street Address:	520 Lake Cook Rd, Suite 500		
City:	Deerfield		
State/Country:	ILLINOIS		
Postal Code:	60015		
Entity Type:	Limited Liability Company: DELAWARE		
Name:	JDP Therapeutics LLC		
Street Address:	520 Lake Cook Rd, Suite 500		
City:	Deerfield		
State/Country:	ILLINOIS		
Postal Code:	60015		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 12			
Property Type	Number	Word Mark	
Registration Number:	3859849	ERGOMAR	
Serial Number:	86900284	TERSERA	
Serial Number:	86900292	TERSERA	
Serial Number:	86900298	TERSERA	
Registration Number:	1402790	ZOLADEX	
Registration Number:	1624402	ZOLADEX	
Registration Number:	3370124	SAFESYSTEM	
Registration Number:	2806847	PRIALT	
Serial Number:	87021069	PRIALT ACCESS & SUPPORT PROGRAM	
Registration Number:	5200148	XERMELO	
Registration Number:	6034081	XERMELO	
Registration Number:	6034082		

OP \$315.00 3859849

CORRESPONDENCE DATA**Fax Number:** 2142207716*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 2146617347**Email:** sspainhour@velaw.com**Correspondent Name:** Shannon Spainhour**Address Line 1:** 2001 Ross Avenue, Suite 3900**Address Line 2:** c/o Vinson & Elkins L.L.P.**Address Line 4:** Dallas, TEXAS 75201

NAME OF SUBMITTER:	Shannon Spainhour
SIGNATURE:	/Shannon Spainhour/
DATE SIGNED:	04/04/2023

Total Attachments: 7

source=TerSera - 2L IP Release [Executed]#page1.tif

source=TerSera - 2L IP Release [Executed]#page2.tif

source=TerSera - 2L IP Release [Executed]#page3.tif

source=TerSera - 2L IP Release [Executed]#page4.tif

source=TerSera - 2L IP Release [Executed]#page5.tif

source=TerSera - 2L IP Release [Executed]#page6.tif

source=TerSera - 2L IP Release [Executed]#page7.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS

This **RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS**, dated as of April 4, 2023 (this “**Release**”), is made by **NEWSTONE CAPITAL PARTNERS, LLC**, in its capacity as agent for Secured Parties (in such capacity, the “**Agent**”) as defined in the Second Lien Guaranty and Security Agreement referred to below. All capitalized terms used, but not otherwise defined herein, shall have the meanings set forth in the Second Lien Guaranty and Security Agreement or in the Intellectual Property Security Agreements referred to below.

WHEREAS, in connection with that certain Second Lien Guaranty and Security Agreement, dated as of March 30, 2017 (as amended, restated, supplemented or otherwise modified from time to time, the “**Guaranty and Security Agreement**”), by and among the Grantors and the Agent, the Grantors, as collateral security for the Secured Obligations, granted to the Agent a security interest in and continuing lien on all of their right, title and interest in, to and under the Collateral, including without limitation, certain Intellectual Property of the Grantors;

WHEREAS, in connection with the Second Lien Guaranty and Security Agreement and pursuant to those certain agreements described on Annex I attached hereto (collectively, the “**Intellectual Property Security Agreements**”), certain of the Grantors granted to the Agent a security interest in their Intellectual Property as Collateral, including the Patent Collateral and Trademark Collateral (each as defined in the Intellectual Property Security Agreements); and

WHEREAS, certain of the Intellectual Property Security Agreements were recorded in the United States Patent and Trademark Office or the United States Copyright Office, as applicable, on the dates and on the reel and frame numbers set forth on Annex I hereto.


NOW THEREFORE, in consideration of the material covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby releases, terminates and discharges, without representation, recourse or warranty whatsoever, all of its rights in, to and under, including its lien on and security interest in, and right of setoff against all such Intellectual Property within Collateral, whether granted pursuant to the Intellectual Property Security Agreements or any other agreement or document delivered in connection with the Pledge and Security Agreement, and the Agent hereby reassigns any and all such right, title and interest (if any) that the Agent may have in, to and under all such Intellectual Property within Collateral to the Grantors.

This Release shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, the Agent has executed this Release as of the date first written above.

NEWSTONE CAPITAL PARTNERS, LLC, as
Agent

By: 
Name: Timothy P. Costello
Title: Managing Director

ANNEX I

Second Lien Patent Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of March 30, 2017 and recorded in the United States Patent and Trademark Security Office on April 14, 2017 at Reel/Frame 042007/0871 covering the following:

PATENT REGISTRATIONS

Grantor	Title / Name	Application No.	Registration No.
TerSera Therapeutics LLC	AUTOMATICALLY OPERABLE SAFETY SHIELD SYSTEM FOR SYRINGES	09/936,859	7118552
TerSera Therapeutics LLC	AUTOMATICALLY OPERABLE SAFETY SHIELD SYSTEM FOR SYRINGES	10/815,014	7220247
TerSera Therapeutics LLC	AUTOMATICALLY OPERABLE SAFETY SHIELD SYSTEM FOR SYRINGES	11/740,598	7500964
TerSera Therapeutics LLC	INJECTION DEVICE WITH PULL OFF STRIP	29/154,724	D483861

Second Lien Patent Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of September 27, 2018, covering the following:

PATENT REGISTRATIONS

Grantor	Subject Matter	Patent No.
TerSera Therapeutics LLC	Composition: Prialt and morphine	7,268,109
TerSera Therapeutics LLC	Composition: Prialt and clonidine or baclofen	7,524,812
TerSera Therapeutics LLC	Composition: 4 different formulations each containing a combination of Prialt and one other drug	7,833,973
TerSera Therapeutics LLC	Method: Administering Prialt and morphine	7,977,307
TerSera Therapeutics LLC	Method: Administering Prialt and baclofen	7,956,030
TerSera Therapeutics LLC	Method: Administering a pharmaceutical formulation comprising Prialt and an analgesic compound of	8,268,774

	hydromorphone, fentanyl, sufentanil, bupivacaine, clonidine, or buprenorphine	
TerSera Therapeutics LLC	Composition and Method for Administering Prialt and bupivacaine	8,513,198
TerSera Therapeutics LLC	Avoiding admixture of Prialt and Morphine	8,653,033
TerSera Therapeutics LLC	Avoiding admixture of Prialt and Morphine	8,765,680
TerSera Therapeutics LLC	A method to treat chronic pain using a specific dose of Prialt and morphine	9,707,270

PATENT APPLICATIONS

Appl. No.	Subject Matter	Owner	Exp. Date
15/651,655	A method to treat chronic pain using a specific dose of Prialt	TerSera Therapeutics LLC	10/1/2024

Patent Security Agreement against JDP Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of May 10, 2019 and recorded in the United States Patent and Trademark Security Office on May 10, 2019 at Reel/Frame 049143/0782 covering the following:

PATENT REGISTRATIONS

Grantor	Title / Name	Application No.	Registration No.
JDP Therapeutics LLC	Non-sedating antihistamine injection formulations and methods of use thereof	12829857	8314083
JDP Therapeutics LLC	Non-sedating antihistamine injection formulations and methods of use thereof	13559954	9119771
JDP Therapeutics LLC	Non-sedating antihistamine injection formulations and methods of use thereof	13940747	9161902
JDP Therapeutics LLC	Non-sedating antihistamine injection formulations and methods of use thereof	13238453	8513259
JDP Therapeutics LLC	Non-sedating antihistamine injection formulations and methods of use thereof	12704089	8263581
JDP Therapeutics LLC	Non-sedating antihistamine injection formulations and methods of use thereof	13644290	9180090

Second Lien Patent Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of September 8, 2020 and recorded in the United States Patent and Trademark Security Office on September 9, 2020 at Reel/Frame 053721/0037 covering the following:

PATENT REGISTRATIONS AND APPLICATIONS

LEXICON REFERENCE	COUNTRY	APPLICATION NUMBER	FILING DATE	PATENT NUMBER	ISSUE DATE
LEX-1002-US-PRV	United States	60754955	Dec 29, 2005		
LEX-1002-US-NP	United States	11638677	Dec. 12, 2006	7723345	May 25, 2007
LEX-1002-US-CNT	United States	12750278	Mar 30, 2010	8063057	Nov 22, 2011
LEX-1002-US-CNT[2]	United States	13290261	Nov 7, 2011	8629156	Jan 14, 2014
LEX-1004-US-PRV	United States	60754785	Dec 29, 2005		
LEX-1004-US-NP	United States	11647517	Dec 28, 2006	7855291	Dec 21, 2010
LEX-1004-US-CIP	United States	12257558	Oct 24, 2008	7897763	Mar 1, 2011
LEX-1004-US-CNT	United States	13024469	Feb 10, 2011	8450532	May 28, 2013
LEX-1005-US-PRV	United States	60874596	Dec 12, 2006		
LEX-1005-US-CNT	United States	12468974	May 20, 2009	7709493	May 4, 2010
LEX-1005-US-CNT[2]	United States	12754341	Apr 5, 2010	7968559	Jun 28, 2011
LEX-1005-US-CNT[3]	United States	13162989	Jun 17, 2011	8772482	Jul 8, 2014
LEX-1005-US-NP	United States	11954000	Dec 11, 2007	7553840	Jun 30, 2009
LEX-1008-US-PRV	United States	60949040	Jul 11, 2007		
LEX-1008-US-NP	United States	12169815	Jul 9, 2008	7875622	Jan 25, 2011
LEX-1008-US-CNT	United States	13006592	Jan 14, 2011	8410121	Apr 2, 2013
LEX-1009-US-PRV	United States	60975846	Sep 28, 2007		
LEX-1009-US-CNT	United States	13486103	Jun 1, 2012	8653094	Feb 18, 2014
LEX-1009-US-NP	United States	12237455	Sep 25, 2008	8193204	Jun 5, 2012
LEX-1010-US-PRV	United States	60957744	Aug 24 2007		
LEX-1010-US-CNT	United States	13160678	Jun 15, 2011	8575362	Nov 5, 2013
LEX-1010-US-DIV	United States	12732311	Mar 26, 2010	7968729	Jun 28, 2011
LEX-1313-US-PRV	United States	61547894	Oct 17, 2011		
LEX-1313-US-CNT[3]	United States	16688658	Nov 19, 2019		
LEX-1314-US-PRV	United States	61410421	Nov 5, 2010		
LEX-1314-US-NP	United States	13288366	Nov 3, 2011	8772483	Jul 8, 2014

Second Lien Trademark Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of March 30, 2017 and recorded in the United States Patent and Trademark Security Office on April 14, 2017 at Reel/Frame 6033/0638 covering the following:

1. REGISTERED TRADEMARKS

Mark Name	App. No.	App. Date	Status	Current Owner	Reg. No.	Reg. Date
ERGOMAR	77/942800	2/23/10	Reg. (G)	TerSera Therapeutics LLC	3859849	10/12/10

2. TRADEMARK APPLICATIONS

Mark Name	App. No.	App. Date	Status	Current Owner	Reg. No.	Reg. Date
TERSERA (CLASS 5)	86/900284	2/08/16	Filed (F)	TerSera Therapeutics LLC		
TERSERA (CLASS 35)	86/900292	2/08/16	Filed (F)	TerSera Therapeutics LLC		
TERSERA (CLASS 42)	86/900298	2/08/16	Filed (F)	TerSera Therapeutics LLC		

3. LICENSED TRADEMARKS

Trademark	App Date / App No.	Registration Date / Registration No.	Status
ZOLADEX	July 1, 1985 / 73545833	July 29, 1986 / 1402790	Registered
ZOLADEX	Dec. 14, 1989 / 74/010646	Nov. 27, 1990 / 1624402	Registered
SAFESYSTEM	Aug. 28, 2002 / 78/158492	Jan. 15, 2008 / 3370124	Registered

Second Lien Trademark Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as agent, dated as of September 27, 2018, covering the following:

REGISTERED TRADEMARKS

Mark Name	Status	Current Owner	Reg. No.	Reg. Date	App No.	Filing Date
PRIALT	Registered	TerSera Therapeutics LLC	2,806,847	1/20/04		
PRIALT ACCESS & SUPPORT PROGRAM (Stylized) & Design	Allowed	TerSera Therapeutics LLC			87/021,069	02-May-16

Second Lien Trademark Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of September 8, 2020 and recorded in the United States Patent and Trademark Security Office on September 9, 2020 at Reel/Frame 7047/0249 covering the following:

REGISTERED TRADEMARKS

Mark Name	Status	Current Owner	Reg. No.	Reg. Date
XERMELO	Registered	TerSera Therapeutics LLC	5200148	05/09/2017
XERMELO [and three-cube design]	Registered	TerSera Therapeutics LLC	6034081	04/14/2020
[three-cube design]	Registered	TerSera Therapeutics LLC	6034082	04/14/2020